Ignite Creation Date:
2024-05-05 @ 5:28 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00465088
Status:
COMPLETED
Last Update Posted:
2011-06-13
First Post:
2007-04-23
Brief Title:
An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin NS to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia SUPREME
Sponsor:
Abbott
Organization:
Abbott
Study Overview
Official Title:
SUPREME A 12-Week Open-Label Multicenter Study to Compare the Lipid Effects of Niacin ER and Simvastatin NS to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia
Status:
COMPLETED
Status Verified Date:
2011-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SUPREME
Brief Summary:
To demonstrate that niacin ER and simvastatin NS tablets when compared to atorvastatin Lipitor Pfizer Inc has superior high-density lipoprotein cholesterol HDL-C elevating effects at Week 12 in subjects with type II hyperlipidemia or mixed dyslipidemia who are currently off lipid-modifying therapy This was a prospective randomized open-label blinded endpoint PROBE study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| M10-013 | None | None | None |